Furthermore, one study reported that co-administration of NAC and metformin for 12 months in patients with nonalcoholic steatohepatitis (NASH) decreased serum FBS, fasting insulin and insulin resistance, HDL-C, and TG levels but did not change serum concentrations of TC (35). This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.